Tiverton Asset Management LLC Buys 29,964 Shares of Merck & Co., Inc. (MRK)

Tiverton Asset Management LLC grew its stake in Merck & Co., Inc. (NYSE:MRK) by 110.1% in the 2nd quarter, according to its most recent filing with the SEC. The firm owned 57,190 shares of the company’s stock after buying an additional 29,964 shares during the quarter. Tiverton Asset Management LLC’s holdings in Merck & Co., Inc. were worth $3,471,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Cobblestone Capital Advisors LLC NY lifted its stake in Merck & Co., Inc. by 0.4% during the second quarter. Cobblestone Capital Advisors LLC NY now owns 187,080 shares of the company’s stock worth $11,356,000 after purchasing an additional 774 shares during the last quarter. Associated Banc Corp lifted its stake in Merck & Co., Inc. by 0.3% during the second quarter. Associated Banc Corp now owns 251,933 shares of the company’s stock worth $15,293,000 after purchasing an additional 776 shares during the last quarter. Checchi Capital Advisers LLC lifted its stake in Merck & Co., Inc. by 3.0% during the second quarter. Checchi Capital Advisers LLC now owns 26,914 shares of the company’s stock worth $1,634,000 after purchasing an additional 792 shares during the last quarter. Nicollet Investment Management Inc. lifted its stake in Merck & Co., Inc. by 2.2% during the second quarter. Nicollet Investment Management Inc. now owns 36,898 shares of the company’s stock worth $2,240,000 after purchasing an additional 805 shares during the last quarter. Finally, Mckinley Capital Management LLC Delaware lifted its stake in Merck & Co., Inc. by 5.6% during the second quarter. Mckinley Capital Management LLC Delaware now owns 15,447 shares of the company’s stock worth $938,000 after purchasing an additional 815 shares during the last quarter. Institutional investors and hedge funds own 72.18% of the company’s stock.

Several research firms recently weighed in on MRK. BMO Capital Markets restated a “buy” rating and set a $70.00 target price on shares of Merck & Co., Inc. in a research note on Sunday, July 22nd. Zacks Investment Research upgraded Merck & Co., Inc. from a “hold” rating to a “buy” rating and set a $79.00 price objective for the company in a research note on Wednesday, September 26th. Jefferies Financial Group reiterated a “hold” rating and issued a $59.00 price objective on shares of Merck & Co., Inc. in a research note on Sunday, July 15th. Bank of America boosted their price objective on Merck & Co., Inc. from $70.00 to $74.00 and gave the company a “buy” rating in a research note on Monday, July 30th. Finally, Morgan Stanley set a $74.00 price objective on Merck & Co., Inc. and gave the company a “buy” rating in a research note on Thursday, August 23rd. Six investment analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $68.55.

Shares of NYSE MRK opened at $71.03 on Monday. The company has a debt-to-equity ratio of 0.61, a current ratio of 1.33 and a quick ratio of 1.04. Merck & Co., Inc. has a twelve month low of $52.83 and a twelve month high of $72.42. The company has a market capitalization of $191.27 billion, a price-to-earnings ratio of 17.85, a PEG ratio of 2.22 and a beta of 0.81.

Merck & Co., Inc. (NYSE:MRK) last issued its quarterly earnings data on Friday, July 27th. The company reported $1.06 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.03 by $0.03. Merck & Co., Inc. had a return on equity of 32.68% and a net margin of 3.67%. The company had revenue of $10.47 billion during the quarter, compared to analysts’ expectations of $10.28 billion. During the same quarter in the previous year, the business earned $1.01 earnings per share. The firm’s revenue for the quarter was up 5.4% on a year-over-year basis. As a group, sell-side analysts anticipate that Merck & Co., Inc. will post 4.27 earnings per share for the current year.

The business also recently announced a quarterly dividend, which was paid on Friday, October 5th. Stockholders of record on Monday, September 17th were issued a $0.48 dividend. This represents a $1.92 dividend on an annualized basis and a dividend yield of 2.70%. The ex-dividend date of this dividend was Friday, September 14th. Merck & Co., Inc.’s payout ratio is currently 48.24%.

In other news, insider Sanat Chattopadhyay sold 29,208 shares of the business’s stock in a transaction that occurred on Friday, August 3rd. The stock was sold at an average price of $65.20, for a total value of $1,904,361.60. Following the transaction, the insider now owns 70,675 shares of the company’s stock, valued at $4,608,010. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, Chairman Kenneth C. Frazier sold 279,850 shares of the business’s stock in a transaction that occurred on Tuesday, October 2nd. The shares were sold at an average price of $72.07, for a total value of $20,168,789.50. Following the completion of the transaction, the chairman now directly owns 971,800 shares in the company, valued at approximately $70,037,626. The disclosure for this sale can be found here. In the last three months, insiders sold 929,360 shares of company stock worth $64,370,599. Corporate insiders own 0.32% of the company’s stock.

About Merck & Co., Inc.

Merck & Co, Inc provides healthcare solutions worldwide. It operates in four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company offers therapeutic and preventive agents to treat cardiovascular diseases, type 2 diabetes, asthma, nasal allergy symptoms, allergic rhinitis, chronic hepatitis C virus, HIV-1 infection, fungal, intra-abdominal infections, hypertension, arthritis and pain, inflammatory, osteoporosis, and fertility diseases.

Further Reading: What are the most popular ETFs

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply